Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritlecitinib in Cicatricial Alopecia
NCT05549934Phase 2Completed
- Start
- Dec 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ritlecitinib tosilate in cicatricial alopecia. Primary endpoints: Safety and Tolerability at 48 weeks and Biomarker Responses at 48 weeks. Started Dec 2022; status: completed.
02
Drugs
ritlecitinib tosilate
03
Conditions
cicatricial alopecia
Beyond the preview
Go deeper on NCT05549934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05549934.